Featured Research

from universities, journals, and other organizations

Combination Antiretroviral Therapy Effective At Reducing HIV Resistance In Mothers And Babies Following Mother-to-child Transmission

Date:
October 28, 2009
Source:
Public Library of Science
Summary:
In a clinical trial investigating mother-to-child HIV transmission in South Africa researchers find that adding two other antiretroviral drugs to single dose nevirapine -- an antiretroviral drug given to women and newborn children during labor and delivery to prevent transmission -- is effective in reducing the drug resistance that nevirapine causes when used by itself.

In a clinical trial investigating mother-to-child HIV transmission in South Africa published this week in PLoS Medicine, Neil Martinson (of the Perinatal HIV Research Unit, Soweto, South Africa) and colleagues find that adding two other antiretroviral drugs to single dose nevirapine -- an antiretroviral drug given to women and newborn children during labor and delivery to prevent transmission -- is effective in reducing the drug resistance that nevirapine causes when used by itself.

Related Articles


Such resistance can compromise later treatment regimens that include the same class of drug as nevirapine. The researchers report that the combination drug regimen -- which involved the addition of a twice-daily dose of zidovudine and lamivudine over several days following a single-dose of nevirapine -- is safe and easy to provide, and effective in reducing subsequent nevirapine resistance in both mothers and those babies that are infec ted despite antiretrovirals.

In a related Perspective, Dara Lehman (of Fred Hutchinson Cancer Research Center, Seattle, Washington) and colleagues, uninvolved with the research, say that assuming that there is not a large amount of lurking resistance not detected by the study, the approach may "strike the right balance of a feasible regimen that minimizes resistance" in resource-poor settings where combination antiretroviral therapy may not be available for longer-term use in pregnancy.

Funding: Boehringer Ingelheim, the developer and manufacturer of nevirapine, funded this trial, designed the study, was involved in data collection, and was responsible for data management and involved in the analysis. The decision to publish and preparation of the manuscript included employees of the sponsor, which gave an assurance that all authors have full access to the trial dataset.

Competing interests: M. Hopley, M. Ekelund, D. B. Hall, and P. Robinson are employed by Boehringer Ingelheim, the sponsor of the study, and D. Mayers was employed by Boehringer Ingelheim at the time of the study.


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. McIntyre et al. Efficacy of Short-Course AZT Plus 3TC to Reduce Nevirapine Resistance in the Prevention of Mother-to-Child HIV Transmission: A Randomized Clinical Trial. PLoS Medicine, 2009; 6 (10): e1000172 DOI: 10.1371/journal.pmed.1000172

Cite This Page:

Public Library of Science. "Combination Antiretroviral Therapy Effective At Reducing HIV Resistance In Mothers And Babies Following Mother-to-child Transmission." ScienceDaily. ScienceDaily, 28 October 2009. <www.sciencedaily.com/releases/2009/10/091026220007.htm>.
Public Library of Science. (2009, October 28). Combination Antiretroviral Therapy Effective At Reducing HIV Resistance In Mothers And Babies Following Mother-to-child Transmission. ScienceDaily. Retrieved January 31, 2015 from www.sciencedaily.com/releases/2009/10/091026220007.htm
Public Library of Science. "Combination Antiretroviral Therapy Effective At Reducing HIV Resistance In Mothers And Babies Following Mother-to-child Transmission." ScienceDaily. www.sciencedaily.com/releases/2009/10/091026220007.htm (accessed January 31, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, January 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC: Get Vaccinated for Measles

CDC: Get Vaccinated for Measles

Reuters - US Online Video (Jan. 30, 2015) The CDC is urging people to get vaccinated for measles amid an outbreak that began at Disneyland and has now infected more than 90 people. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Obama To Outline New Plan For Personalized Medicine

Obama To Outline New Plan For Personalized Medicine

Newsy (Jan. 30, 2015) President Obama is expected to speak with drugmakers Friday about his Precision Medicine Initiative first introduced last week. Video provided by Newsy
Powered by NewsLook.com
NFL Concussions Down; Still on Parents' Minds

NFL Concussions Down; Still on Parents' Minds

AP (Jan. 30, 2015) The NFL announced this week that the number of game concussions dropped by a quarter over last season. Still, the dangers of the sport still weigh on players, and parents&apos; minds. (Jan. 30) Video provided by AP
Powered by NewsLook.com
U.S. Wants to Analyze DNA from 1 Million People

U.S. Wants to Analyze DNA from 1 Million People

Reuters - US Online Video (Jan. 30, 2015) The U.S. has proposed analyzing genetic information from more than 1 million American volunteers to learn how genetic variants affect health and disease. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins